D047069Chemicals & DrugsD03.383.129.539.850230.997756Pyrazolonesprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson11159796Joshi AS, Pieniaszek HJ, Vokes EE, Vogelzang NJ, Davidson AF, Richards LE, Chai MF, Finizio M, Ratain MJDrug metabolism and disposition: the biological fate of chemicalsElimination pathways of [14C]losoxantrone in four cancer patients. Drug Metab Dispos. 2001 Feb; 29(2):96-9.Drug Metab Dispos2001-02-01T00:00:002001Elimination pathways of [14C]losoxantrone in four cancer patients.Medicine-Hematology and Oncology11870533Goh BC, Vokes EE, Joshi A, Ratain MJBritish journal of cancerPhase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours. Br J Cancer. 2002 Feb 12; 86(4):534-9.Br J Cancer2002-02-12T00:00:002002Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours.0.4158170.03355922research area of0.2158070.1345393subject area forUniversity of ChicagoMark J.RatainMark J. Ratain41.78927490000000-87.601250000000001401Ratain, Mark J.ProfessorClaytonCrawleyClayton Crawley41.78927490000000-87.601250000000001831Crawley, Claytontrue1true1ProfessorProfessor25893291Giotopoulos G, Chan WI, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E, Campbell PJ, Göttgens B, Van Deursen JM, Cole PA, Huntly BJOncogeneThe epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia. Oncogene. 2016 Jan 21; 35(3):279-89.Oncogene2015-04-20T00:00:002015The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.